Clinical Trials Browser

Breast Neoplasms × durvalumab × Clear all

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT06103864 2026-03-31

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT02484404 2026-03-25

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Phase 1/2 Active not recruiting

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Phase 3 Active not recruiting

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04176848 2026-02-18

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Phase 2 Active not recruiting

15 enrolled 7 charts

Breast Neoplasms

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT06954480 2025-11-19

DIAMOND

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05795101 2025-09-19

TRUDI

Phase 2 Recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05498155 2025-06-10

OlympiaN

Phase 2 Active not recruiting

Breast Neoplasms

NCT03594396 2025-04-17

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03820141 2025-03-10

DTP

Phase 2 Active not recruiting

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT03518606 2025-01-15

MOVIE

Phase 1/2 Completed

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03875573 2024-12-20

Neo-CheckRay

Phase 2 Active not recruiting

Breast Neoplasms

NCT03616886 2024-12-19

SYNERGY

Phase 1/2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03356860 2024-11-20

B-IMMUNE

Phase 1/2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06508216 2024-07-22

COMPASS-TNBC

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 Recruiting

Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02649686 2023-08-04

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Phase 1 Completed

Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT02489448 2022-10-26

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Phase 1/2 Completed

68 enrolled 9 charts

Breast Neoplasms

NCT01975831 2022-10-12

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Phase 1 Completed

104 enrolled 23 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02563925 2022-08-03

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Phase NA Completed

28 enrolled 9 charts

Breast Neoplasms

NCT03874325 2022-05-31

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2 Terminated

17 enrolled 10 charts

Breast Neoplasms

NCT02536794 2022-05-17

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

30 enrolled 18 charts

Breast Neoplasms

NCT03608865 2022-01-03

Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

Phase 2 Completed

Breast Neoplasms

NCT03872505 2021-08-25

PANDoRA

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02685059 2021-02-15

GeparNuevo

Phase 2 Completed

Breast Neoplasms

NCT02725489 2021-01-27

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Phase 2 Completed

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

NCT02997995 2020-09-30

ULTIMATE

Phase 2 Completed

Breast Neoplasms

NCT03430518 2020-08-05

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02628132 2020-07-07

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Phase 1/2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT02802098 2020-06-19

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1/2 Completed

124 enrolled 17 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

NCT02669914 2018-11-06

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Phase 2 Terminated

4 enrolled 12 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms